Kyung Dong Pharmaceutical Co., Ltd. Stock price

Equities

A011040

KR7011040003

Pharmaceuticals

End-of-day quote Korea S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
6,530 KRW -0.31% Intraday chart for Kyung Dong Pharmaceutical Co., Ltd. +0.31% -1.21%
Sales 2021 178B 132M Sales 2022 183B 135M Capitalization 214B 158M
Net income 2021 12.67B 9.39M Net income 2022 12.16B 9.01M EV / Sales 2021 1.51 x
Net cash position 2021 45.71B 33.87M Net cash position 2022 18.26B 13.53M EV / Sales 2022 1.07 x
P/E ratio 2021
24.9 x
P/E ratio 2022
17.6 x
Employees 385
Yield 2021
4.37%
Yield 2022
5.08%
Free-Float 43.63%
More Fundamentals * Assessed data
Dynamic Chart
Kyung Dong Pharmaceutical Co., Ltd. announces an Equity Buyback for 200,000 shares. CI
Kyung Dong Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Kyung Dong Pharmaceutical Co., Ltd.(KOSDAQ:A011040) dropped from S&P Global BMI Index CI
Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Tranche Update on Kyung Dong Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 16, 2022. CI
Kyung Dong Pharmaceutical Co., Ltd.'s Equity Buyback announced on September 16, 202, has closed with 100,000 shares, representing 0.37% for KRW 749.64 million. CI
Kyung Dong Pharmaceutical Co., Ltd. announces an Equity Buyback for 100,000 shares. CI
Kyung Dong Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Eight South Korean Firms to Donate $2.4 Million Worth of Medicine to Ukraine MT
Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
More news
1 day-0.31%
1 week+0.31%
Current month+2.19%
1 month+1.87%
3 months-0.76%
6 months-2.39%
Current year-1.21%
More quotes
1 week
6 490.00
Extreme 6490
6 660.00
1 month
6 340.00
Extreme 6340
6 660.00
Current year
6 200.00
Extreme 6200
6 690.00
1 year
6 190.00
Extreme 6190
8 420.00
3 years
6 190.00
Extreme 6190
17 650.00
5 years
5 830.00
Extreme 5830
18 300.00
10 years
5 830.00
Extreme 5830
18 300.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 41 06-10-31
Director of Finance/CFO 51 -
Comptroller/Controller/Auditor 84 -
Members of the board TitleAgeSince
Chief Executive Officer 41 06-10-31
Director/Board Member 79 -
Director/Board Member 43 -
More insiders
Date Price Change Volume
24-03-27 6,530 -0.31% 36 428
24-03-27 6,550 -1.06% 54,604
24-03-26 6,620 -0.30% 61,536
24-03-25 6,640 +0.61% 64,643
24-03-22 6,600 +1.07% 88,919

End-of-day quote Korea S.E., March 27, 2024

More quotes
KYUNG DONG PHARMACEUTICAL CO.,LTD. is a Korea-based company engaged in the manufacture and marketing of pharmaceutical products. The Company's products include liver therapies, gastrointestinal drugs, antimigraine drugs, antiviral, anti-obesity medications, antibacterial drugs, antidiabetic drugs, antifungal, allergy medications, antispasmodics, antihistamines, vitamins, as well as drugs for osteoporosis, cardiovascular, muscle relaxant, neuropathic and other diseases. It also provides various over-the-counter (OTC) drugs, such as anti-inflammatory medicines, antiviral drugs, antihistamine drugs, gastrointestinal drugs and others. In addition, the Company engages in the leasing of real estate, and distribution of snowboards and health functional food.
More about the company
  1. Stock
  2. Equities
  3. Stock Kyung Dong Pharmaceutical Co., Ltd. - Korea S.E.